Student Assistant in Online Marketing (Tracking and Analytics and SEO)

Last updated: 2025.08.28

First market launch of the adrenaline nasal spray, EURneffy®, for treatment of adults and children in Germany

Last updated: 2025.06.26

ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025

Last updated: 2025.06.16

ALK participates at Jefferies Global Healthcare Conference 2025 in New York

Last updated: 2025.06.04

Three-month interim report (Q1) 2025 (unaudited)

Last updated: 2025.05.09

ITULATEK® approved for treatment of children and adolescents in Canada

Last updated: 2025.05.08

ALK enters into neffy® co-promotion agreement in the USA

Last updated: 2025.05.02

Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025

Last updated: 2025.04.29

ITULAZAX® tree pollen tablet approved for treatment of children in Europe

Last updated: 2025.04.23

Grant of share-based long-term incentive instruments to members of the Board of Management and key employees

Last updated: 2025.04.03